Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex dose-finding for reversal of deep rocuronium neuromuscular block
2019-000709-55Phase 4Completed
- Sponsor
- UZ Brussel
- Start
- Jan 2020
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of Sugammadex in neuromuscular block (NMB), sponsored by UZ Brussel. Primary endpoints: ED50 of sugammadex (stage 1) and ED50 of sugammadex (later stage). Started Jan 2020; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on 2019-000709-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000709-55.